News | March 09, 2023
Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
Resomer used in commercial 3D-printed implants for both soft and hard tissue applications
Resomer used in commercial 3D-printed implants for both soft and hard tissue applications
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Cipla has received 8 inspectional observations in Form 483
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Subscribe To Our Newsletter & Stay Updated
